AI Article Synopsis
- Thyroid nodules are common and usually benign, but thyroidectomy poses risks, leading to interest in alternatives like high-intensity focused ultrasound (HIFU) ablation.
- A systematic review followed PRISMA guidelines, evaluating 11 studies that focused on single-session HIFU therapy for benign thyroid nodules.
- The treatment showed a volume reduction rate of over 50% in most cases, with no major complications, confirming that single-session HIFU is a safe and effective option.
Article Abstract
Background: Thyroid nodules are common; the majority of them are benign and asymptomatic. Thyroidectomy might be an option; however, the frequency of post-operative complications mandates the development of alternative approaches, such as high-intensity focused ultrasound ablation (HIFU). HIFU induces thermal destruction without penetrating the skin. The present systematic review aims to synthesize all available data, evaluating studies with single-session HIFU therapy and investigating its efficacy.
Materials And Methods: This systematic review was conducted in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and MetaAnalyses). Eligible articles were identified by a search of Medline bibliographic database (PubMed) and Cochrane Library. Out of 39 results, 11 articles were considered to meet the inclusion criteria.
Results: All eligible studies included patients with solid or predominantly solid benign thyroid nodules. All patients were treated with the same HIFU device. The success rate of the method was defined in the majority, with the volume reduction rate (VRR) over 50% from baseline. The mean or median VRR ranged from 48.7 to 70.41%, depending on the last follow-up date. No major complications were observed.
Conclusion: Single-session HIFU is safe and effective for the treatment of benign thyroid nodules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17434440.2020.1806053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Care for Primary Glomerulonephritis: The Role of Thyroid Evaluation.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Background: The coexistence of primary glomerulonephritis and autoimmune thyroid disease has not been investigated.
Objective: This study aimed to assess thyroid morphology using sonography, determine the prevalence of autoimmune thyroid disorders, and evaluate thyroid function status in patients diagnosed with primary glomerulonephritis.
Materials And Methods: This single-center cross-sectional and observational study included 58 consecutive patients with primary glomerulonephritis and 58 healthy controls (HC).
Alectinib treatment for 2 non-small cell lung carcinoma patients carrying different novel fusions.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011.
The genomic fusions of the anaplastic lymphoma kinase () gene have been widely recognized as effective therapeutic targets for non-small cell lung carcinoma (NSCLC). The Second Xiangya Hospital of Central South University has treated 2 NSCLC patients with 2 distinct novel gene fusions. Case 1 was a 55-year-old male with a solid nodule located in the right hilar lobe on enhanced CT scan.
View Article and Find Full Text PDFCirculating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis.
BJS Open
December 2024
Institute of Cardiovascular Sciences, University College London, London, UK.
Background: While most thyroid nodules are benign, 7-15% are malignant. Patients with indeterminate thyroid nodules (specifically Bethesda IV/Thy3f) often undergo diagnostic hemithyroidectomy to reach a diagnosis on final histology. The aim of this study was to assess the feasibility of circulating large extracellular vesicles as diagnostic biomarkers in patients presenting with Thy3f thyroid nodules.
View Article and Find Full Text PDFRadiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline.
Korean J Radiol
January 2025
Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus.
View Article and Find Full Text PDFIntranodular Thyroid Metastasis of a Large Cell Neuroendocrine Carcinoma of the Endometrium.
Clin Nucl Med
January 2025
From the Institut Curie, Department of Nuclear Medicine, Saint-Cloud.
A 64-year-old woman underwent initial 18F-FDG PET/CT staging for a suspicious endometrial mass, which showed high uptake in the endometrial mass and a focal uptake in a known left thyroid nodule. Histology revealed a high-grade large cell neuroendocrine carcinoma of the endometrium with FIGO (International Federation of Gynecology and Obstetrics) stage Ib. Further explorations revealed a synchronous thyroid metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!